Crystals of pyrazolopyridine compounds and their preparation method
Pyrazolopyridine compounds in defined crystalline forms provide effective RET kinase inhibition and tumor growth suppression, addressing the need for RET protein-targeted therapies in cancers and intestinal disorders.
Patent Information
- Application Number
- JP2023514032
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-13
- Filing Date
- 2021-09-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-09-26
Smart Images

Figure 0007590550000050 
Figure 0007590550000051 
Figure 0007590550000052
Abstract
Description
[Technical field]
[0001] This application claims priority to Chinese patent application CN202011051252.9, filed on September 29, 2020, Chinese patent application CN202011118921.X, filed on October 19, 2020, and Chinese patent application CN202110051653.2, filed on January 13, 2021.
[0002] The present invention relates to crystalline forms of the compounds of Formula (II) to Formula (VIII), the compounds of Formula (I) to Formula (VIII-1) and methods for preparing the same, and further includes the use of said crystalline forms in the preparation of a medicament for treating related diseases. [Background technology]
[0003] RET protein is a tyrosine kinase receptor RTK and a transmembrane glycoprotein, which is expressed by the proto-oncogene RET (REarranged during Transfection) located on chromosome 10. It plays an important role in the development of the kidney and enteric nervous system at the embryonic stage, and is also important for the stability in various tissues, such as neural cells, neuroendocrine cells, hematopoietic tissues, and male germ cells. Unlike other RTKs, RET does not directly bind to ligand molecules such as neurotrophin (artemin), glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin, which belong to the GNDF family of ligands (GFLs). These ligands, GFLs, generally bind to GDNF family receptor α (GFRα), and the formed GFLs-GFRα complex mediates self-dimerization of the RET protein, triggering trans-autophosphorylation of tyrosine on the intracellular domain, recruiting associated adaptor proteins, and activating signal transduction cascades such as cell proliferation. Related signal pathways include MAPK, PI3K, JAK-STAT, PKA, and PKC.
[0004] There are two main mechanisms of oncogenic activation of RET. The first is the formation of new fusion proteins by chromosomal rearrangements, typically a protein fusion between the kinase domain of RET and a domain that contains self-dimerization. The second is direct or indirect activation of RET kinase activity by RET mutations. These changes in somatic or germline levels are involved in the pathogenesis of multiple types of cancer. 5%-10% of patients with papillary thyroid cancer have RET chromosomal rearrangements, while 60% of patients in medullary thyroid cancer have RET point mutations, and 10%-20% of all thyroid cancer patients have RET fusions, of which CCDC6 and NCOA4 are the most common, and approximately 1%-2% of all NSCLC patients have RET fusion proteins, of which KIF5B-RET is the most common.
[0005] In summary, multiple types of tumors and intestinal disorders, such as allergic bowel syndrome, all have abnormal RET expression or activation, so RET inhibitors have potential clinical value in tumors and intestinal disorders. Summary of the Invention
[0006] The present invention provides compounds represented by formulas (II) to (VIII), [ka] Among them, n2, n3, n4, n5, n6, n7 and n8 are selected from the range of 0.8 to 1.5.
[0007] In some embodiments of the present invention, n2, n3, n4, n5, n6, n7, and n8 are each independently selected from 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, and 1.5.
[0008] In some aspects of the invention, the compound is [ka] is selected from the group consisting of:
[0009] The present invention provides crystalline form A of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 16.30±0.20°, 21.69±0.20° and 24.63±0.20°. [ka]
[0010] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69±0.20°, and 24.63±0.20°.
[0011] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 7.79±0.20°, 9.58±0.20°, 12.61±0.20°, 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69±0.20°, and 24.63±0.20°.
[0012] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form A has characteristic diffraction peaks at 2θ angles of 6.19±0.20°, 7.79±0.20°, 9.58±0.20°, 12.61±0.20°, 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 17.65±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 20.45±0.20°, 21.69±0.20°, 23.38±0.20°, 24.63±0.20°, and 25.29±0.20°.
[0013] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form A has characteristic diffraction peaks at 2θ angles of 6.19°, 7.79°, 9.21°, 9.58°, 10.32°, 12.61°, 14.88°, 15.10°, 15.51°, 16.30°, 16.60°, 17.65°, 18.49°, 19.16°, 19.70°, 20.03°, 20.45°, 21.69°, 22.24°, 22.83°, 23.38°, 24.63°, 25.29°, 25.76°, 27.70°, 28.34°, and 29.06°.
[0014] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form A has characteristic diffraction peaks at 2θ angles of 16.30±0.20°, 21.69±0.20°, and has characteristic diffraction peaks at 2θ angles of 24.63±0.20°, and / or 6.19±0.20°, and / or 7.79±0.20°, and / or 9.21±0.20°, and / or 9.58±0.20°, and / or 10.32±0.20°, and / or 12.61±0.20°, and / or 14.88±0.20°, and / or 15.1±0.20°, and / or 15.51±0.20°, and / or 16.6±0.20°, and / or 17.65±0.20°, and / or 18.49±0.20°, and / or 19.16±0.20°, and / or 19.7±0.20°, and / or 20.03±0.20°, and / or 20.45±0.20°, and / or 22.24±0.20°, and / or 22.83±0.20°, and / or 23.38±0.20°, and / or 25.29±0.20°, and / or 25.76±0.20°, and / or 27.7±0.20°, and / or 28.34±0.20°, and / or 29.06±0.20°.
[0015] In some embodiments of the present invention, the XRPD spectrum of crystalline form A is shown in FIG.
[0016] In some embodiments of the present invention, the XRPD spectrum of crystalline form A is shown in FIG.
[0017] In some embodiments of the present invention, the XRPD spectral analysis data of the crystalline form A is shown in Table 1-1: [Table 1]
[0018] In some embodiments of the present invention, the XRPD spectral analysis data of the crystalline form A is shown in Table 1-2: [Table 2]
[0019] In some embodiments of the present invention, the differential scanning calorimetry curve of crystalline form A has an onset of one endothermic peak at 188.7±2° C.
[0020] In some embodiments of the present invention, the DSC spectrum of the crystalline form A is shown in FIG.
[0021] In some embodiments of the present invention, the thermogravimetric analysis curve of said crystalline form A reaches a weight loss of 1.20% at 180.0±3° C.
[0022] In some embodiments of the present invention, the TGA spectrum of the crystalline form A is shown in FIG.
[0023] The present invention provides crystalline form B of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 6.66±0.20°, 17.97±0.20° and 22.63±0.20°.
[0024] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form B has characteristic diffraction peaks at 2θ angles of 6.66±0.20°, 8.50±0.20°, 13.30±0.20°, 16.14±0.20°, 16.70±0.20°, 17.97±0.20°, 19.66±0.20°, and 22.63±0.20°.
[0025] In some embodiments of the present invention, the XRPD spectrum of crystalline form B is shown in FIG.
[0026] In some embodiments of the present invention, the XRPD spectral analysis data of the crystalline form B is shown in Table 2: [Table 3]
[0027] The present invention provides crystalline form C of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 16.66±0.20°, 19.22±0.20° and 20.99±0.20°.
[0028] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form C has characteristic diffraction peaks at 2θ angles of 9.08±0.20°, 12.06±0.20°, 16.15±0.20°, 16.66±0.20°, 17.13±0.20°, 19.22±0.20°, 20.99±0.20°, and 24.52±0.20°.
[0029] In some embodiments of the present invention, the XRPD spectrum of crystalline form C is shown in FIG.
[0030] In some embodiments of the present invention, the XRPD spectral analysis data of crystalline form C is shown in Table 3: [Table 4]
[0031] In some embodiments of the present invention, the differential scanning calorimetry curve of crystalline Form C has an onset of one endothermic peak at 171.7±2° C.
[0032] In some embodiments of the present invention, the DSC spectrum of the crystalline form C is shown in FIG.
[0033] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form C reaches a weight loss of 10.08% at 140.0±3° C.
[0034] In some embodiments of the present invention, the TGA spectrum of the crystalline form C is shown in FIG.
[0035] The present invention provides crystalline form D of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 4.79±0.20°, 14.89±0.20° and 16.70±0.20°.
[0036] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form D has characteristic diffraction peaks at 2θ angles of 4.79±0.20°, 6.61±0.20°, 7.16±0.20°, 14.89±0.20°, 16.09±0.20°, 16.70±0.20°, 19.40±0.20°, and 20.73±0.20°.
[0037] In some embodiments of the present invention, the XRPD spectrum of crystalline form D is shown in FIG.
[0038] In some embodiments of the present invention, the XRPD spectral analysis data of crystalline form D is shown in Table 4: [Table 5]
[0039] The present invention provides crystalline form E of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 8.01±0.20°, 17.80±0.20° and 19.14±0.20°.
[0040] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form E has characteristic diffraction peaks at 2θ angles of 8.01±0.20°, 14.15±0.20°, 14.84±0.20°, 16.29±0.20°, 17.23±0.20°, 17.80±0.20°, 18.28±0.20°, and 19.14±0.20°.
[0041] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form E has characteristic diffraction peaks at 2θ angles of 5.98±0.20°, 8.01±0.20°, 9.21±0.20°, 12.9±0.20°, 14.15±0.20°, 14.84±0.20°, 16.29±0.20°, 17.23±0.20°, 17.8±0.20°, 18.28±0.20°, 19.14±0.20°, and 20.7±0.20°.
[0042] In some embodiments of the present invention, the XRPD spectrum of crystalline form E is shown in FIG.
[0043] In some embodiments of the present invention, the XRPD spectral analysis data of crystalline form E is shown in Table 5: [Table 6]
[0044] In some embodiments of the present invention, the differential scanning calorimetry curve for crystalline Form E has an onset of one endothermic peak at 170.6±2°C and another endothermic peak at 189.1±2°C.
[0045] In some embodiments of the present invention, the DSC spectrum of the crystalline form E is shown in FIG.
[0046] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form E reaches a weight loss of 5.59% at 150.0±3° C.
[0047] In some embodiments of the present invention, the TGA spectrum of the crystalline form E is shown in FIG.
[0048] The present invention provides crystalline form F of compound of formula (I), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 4.95±0.20°, 7.13±0.20° and 16.55±0.20°.
[0049] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form F has characteristic diffraction peaks at 2θ angles of 4.95±0.20°, 7.13±0.20°, 14.75±0.20°, 16.55±0.20°, 23.62±0.20°, and 24.96±0.20°.
[0050] In some embodiments of the present invention, the XRPD spectrum of crystalline form F is shown in FIG.
[0051] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form F is shown in Table 6: [Table 7]
[0052] The present invention provides crystalline form G of compound of formula (II-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 11.98±0.20°, 17.90±0.20°, and 21.56±0.20°. [ka]
[0053] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form G has characteristic diffraction peaks at 2θ angles of 11.98±0.20°, 12.39±0.20°, 16.53±0.20°, 17.90±0.20°, 21.56±0.20°, 23.36±0.20°, 24.05±0.20°, and 28.04±0.20°.
[0054] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form G has characteristic diffraction peaks at 2θ angles of 11.98±0.20°, 12.39±0.20°, 14.79±0.20°, 16.53±0.20°, 17.90±0.20°, 21.56±0.20°, 23.36±0.20°, 24.05±0.20°, 24.58±0.20°, 25.27±0.20°, 26.81±0.20°, and 28.04±0.20°.
[0055] In some embodiments of the present invention, the XRPD spectrum of crystalline form G is shown in FIG.
[0056] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form G is shown in Table 7: [Table 8]
[0057] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form G reaches a weight loss of 4.11% at 110.0±3° C.
[0058] In some embodiments of the present invention, the TGA spectrum of the crystalline form G is shown in FIG.
[0059] The present invention provides crystalline form H of compound of formula (II-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 4.90±0.20°, 12.05±0.20°, and 18.24±0.20°.
[0060] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form H has characteristic diffraction peaks at 2θ angles of 4.90±0.20°, 6.49±0.20°, 12.05±0.20°, 16.75±0.20°, 18.24±0.20°, 19.55±0.20°, 20.22±0.20°, and 22.06±0.20°.
[0061] In some embodiments of the present invention, the XRPD spectrum of crystalline form H is shown in FIG.
[0062] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form H is shown in Table 8: [Table 9]
[0063] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form H reaches a weight loss of 2.47% at 160.0±3° C.
[0064] In some embodiments of the present invention, the TGA spectrum of the crystalline form H is shown in FIG.
[0065] The present invention provides crystalline form I of compound of formula (III-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 4.84±0.20°, 19.22±0.20°, and 19.72±0.20°. [ka]
[0066] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline Form I has characteristic diffraction peaks at 2θ angles of 4.84±0.20°, 12.84±0.20°, 13.42±0.20°, 14.40±0.20°, 19.22±0.20°, 19.72±0.20°, 22.46±0.20°, and 30.87±0.20°.
[0067] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form I has characteristic diffraction peaks at 2θ angles of 4.84±0.20°, 12.84±0.20°, 13.42±0.20°, 14.40±0.20°, 15.80±0.20°, 16.89±0.20°, 18.21±0.20°, 19.22±0.20°, 19.72±0.20°, 22.46±0.20°, 24.94±0.20°, and 30.87±0.20°.
[0068] In some embodiments of the present invention, the XRPD spectrum of crystalline Form I is shown in FIG.
[0069] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form I is shown in Table 9: [Table 10]
[0070] In some embodiments of the present invention, the differential scanning calorimetry curve for crystalline Form I has an onset of one endothermic peak at 203.6±2°C.
[0071] In some embodiments of the present invention, the DSC spectrum of the crystalline form I is shown in FIG.
[0072] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I reaches a weight loss of 2.04% at 180.0±3° C.
[0073] In some embodiments of the present invention, the TGA spectrum of the crystalline form I is shown in FIG.
[0074] The present invention provides crystalline form J of compound of formula (IV-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 8.62±0.20°, 11.12±0.20°, and 17.11±0.20°. [ka]
[0075] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form J has characteristic diffraction peaks at 2θ angles of 6.53±0.20°, 8.62±0.20°, 11.12±0.20°, 12.26±0.20°, 17.11±0.20°, 19.71±0.20°, and 21.77±0.20°.
[0076] In some embodiments of the present invention, the XRPD spectrum of crystalline form J is shown in FIG.
[0077] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form J is shown in Table 10: [Table 11]
[0078] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form J reaches a weight loss of 4.67% at 130.0±3° C.
[0079] In some embodiments of the present invention, the TGA spectrum of the crystalline form J is shown in FIG.
[0080] The present invention provides crystalline form K of compound of formula (V-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 12.63±0.20°, 17.95±0.20°, and 21.66±0.20°. [ka]
[0081] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form K has characteristic diffraction peaks at 2θ angles of 12.63±0.20°, 15.47±0.20°, 16.27±0.20°, 17.49±0.20°, 17.95±0.20°, 19.13±0.20°, 21.66±0.20°, and 24.99±0.20°.
[0082] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form K has characteristic diffraction peaks at 2θ angles of 10.21±0.20°, 12.63±0.20°, 15.47±0.20°, 16.27±0.20°, 17.95±0.20°, 19.13±0.20°, 20.00±0.20°, 21.66±0.20°, 22.51±0.20°, 23.97±0.20°, 24.99±0.20°, and 28.39±0.20°.
[0083] In some embodiments of the present invention, the XRPD spectrum of crystalline form K is shown in FIG.
[0084] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form K is shown in Table 11: [Table 12]
[0085] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form K reaches a weight loss of 5.03% at 140.0±3° C.
[0086] In some embodiments of the present invention, the TGA spectrum of the crystalline form K is shown in FIG.
[0087] The present invention provides crystalline form L of compound of formula (V-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 5.93±0.20°, 13.45±0.20°, and 20.70±0.20°.
[0088] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form L has characteristic diffraction peaks at 2θ angles of 5.93±0.20°, 13.45±0.20°, 15.22±0.20°, 17.75±0.20°, 20.70±0.20°, 22.91±0.20°, 26.34±0.20°, and 27.80±0.20°.
[0089] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form L has characteristic diffraction peaks at 2θ angles of 5.93±0.20°, 10.37±0.20°, 13.45±0.20°, 15.22±0.20°, 16.70±0.20°, 17.75±0.20°, 18.56±0.20°, 20.70±0.20°, 22.91±0.20°, 25.35±0.20°, 26.34±0.20°, and 27.80±0.20°.
[0090] In some embodiments of the present invention, the XRPD spectrum of crystalline form L is shown in FIG.
[0091] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form L is shown in Table 12: [Table 13]
[0092] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form L reaches a weight loss of 5.24% at 110.0±3° C.
[0093] In some embodiments of the present invention, the TGA spectrum of the crystalline form L is shown in FIG.
[0094] The present invention provides a crystalline form M of compound of formula (VI-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 8.52±0.20°, 16.75±0.20°, 18.07±0.20°, and 21.72±0.20°. [ka]
[0095] In some embodiments of the present invention, the XRPD spectrum of crystalline form M is shown in FIG.
[0096] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form M is shown in Table 13: [Table 14]
[0097] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form M reaches a weight loss of 5.19% at 120.0±3° C.
[0098] In some embodiments of the present invention, the TGA spectrum of crystalline form M is shown in FIG.
[0099] The present invention provides crystalline form N of compound of formula (VII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 18.53±0.20°, 19.05±0.20°, and 19.98±0.20°. [ka]
[0100] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form N has characteristic diffraction peaks at 2θ angles of 9.98±0.20°, 11.71±0.20°, 12.25±0.20°, 13.24±0.20°, 16.19±0.20°, 18.53±0.20°, 19.05±0.20°, and 19.98±0.20°.
[0101] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form N has characteristic diffraction peaks at 2θ angles of 5.05±0.20°, 9.98±0.20°, 11.71±0.20°, 12.25±0.20°, 13.24±0.20°, 14.35±0.20°, 16.19±0.20°, 18.53±0.20°, 19.05±0.20°, 19.98±0.20°, 20.91±0.20°, and 24.56±0.20°.
[0102] In some embodiments of the present invention, the XRPD spectrum of crystalline form N is shown in FIG.
[0103] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline Form N is shown in Table 14: [Table 15]
[0104] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form N reaches a weight loss of 3.19% at 160.0±3° C.
[0105] In some embodiments of the present invention, the TGA spectrum of the crystalline form N is shown in FIG.
[0106] The present invention provides crystalline form O of compound of formula (VII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 10.39±0.20°, 12.98±0.20°, and 18.17±0.20°.
[0107] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form O has characteristic diffraction peaks at 2θ angles of 10.39±0.20°, 11.33±0.20°, 12.98±0.20°, 15.62±0.20°, 18.17±0.20°, 19.96±0.20°, 21.54±0.20°, and 22.91±0.20°.
[0108] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form O has characteristic diffraction peaks at 2θ angles of 7.75±0.20°, 10.39±0.20°, 11.33±0.20°, 12.98±0.20°, 15.62±0.20°, 16.65±0.20°, 18.17±0.20°, 19.04±0.20°, 19.96±0.20°, 21.54±0.20°, 22.91±0.20°, and 24.05±0.20°.
[0109] In some embodiments of the present invention, the XRPD spectrum of crystalline form O is shown in FIG.
[0110] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form O is shown in Table 15: [Table 16]
[0111] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form O reaches a weight loss of 9.32% at 140.0±3° C.
[0112] In some embodiments of the present invention, the TGA spectrum of crystalline form O is shown in FIG.
[0113] The present invention provides crystalline form P of compound of formula (VII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 6.49±0.20°, 11.83±0.20°, and 25.14±0.20°.
[0114] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form P has characteristic diffraction peaks at 2θ angles of 6.49±0.20°, 7.79±0.20°, 10.90±0.20°, 11.83±0.20°, 12.87±0.20°, 14.82±0.20°, 18.53±0.20°, and 25.14±0.20°.
[0115] In some embodiments of the present invention, the XRPD spectrum of crystalline form P is shown in FIG.
[0116] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form P is shown in Table 16: [Table 17]
[0117] In some embodiments of the present invention, the thermogravimetric analysis curve of crystalline form P reaches a weight loss of 4.58% at 90.0±3° C.
[0118] In some embodiments of the present invention, the TGA spectrum of crystalline form P is shown in FIG.
[0119] The present invention provides a crystalline form Q of compound of formula (VIII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 3.39±0.20°, 6.75±0.20°, and 13.73±0.20°. [ka]
[0120] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form Q has characteristic diffraction peaks at 2θ angles of 3.39±0.20°, 5.88±0.20°, 6.75±0.20°, 7.94±0.20°, 10.72±0.20°, 13.73±0.20°, 16.91±0.20°, and 19.15±0.20°.
[0121] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form Q has characteristic diffraction peaks at 2θ angles of 3.39±0.20°, 5.88±0.20°, 6.75±0.20°, 7.94±0.20°, 9.20±0.20°, 10.72±0.20°, 13.73±0.20°, 16.28±0.20°, 16.91±0.20°, 18.51±0.20°, 19.15±0.20°, and 21.66±0.20°.
[0122] The present invention provides a crystalline form Q of compound of formula (VIII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 6.75±0.20°, 10.72±0.20°, and 13.73±0.20°. [ka]
[0123] In some embodiments of the present invention, the powder X-ray diffraction pattern of crystalline form Q has characteristic diffraction peaks at 2θ angles of 5.88±0.20°, 6.75±0.20°, 7.94±0.20°, 10.72±0.20°, 13.73±0.20°, 16.91±0.20°, 19.15±0.20°, and 24.60±0.20°.
[0124] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form Q has characteristic diffraction peaks at 2θ angles of 5.88±0.20°, 6.75±0.20°, 7.94±0.20°, 9.20±0.20°, 10.72±0.20°, 13.73±0.20°, 16.28±0.20°, 16.91±0.20°, 18.51±0.20°, 19.15±0.20°, 21.66±0.20°, and 24.60±0.20°.
[0125] In some embodiments of the present invention, the XRPD spectrum of crystalline form Q is shown in FIG.
[0126] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form Q is shown in Table 17: [Table 18]
[0127] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form Q reaches a weight loss of 3.96% at 150.0±3° C.
[0128] In some embodiments of the present invention, the TGA spectrum of the crystalline form Q is shown in FIG.
[0129] The present invention provides a crystalline form R of compound of formula (VIII-1), characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 16.28±0.20°, 21.67±0.20°, and 24.59±0.20°.
[0130] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form R has characteristic diffraction peaks at 2θ angles of 14.85±0.20°, 15.49±0.20°, 16.28±0.20°, 18.48±0.20°, 19.13±0.20°, 19.68±0.20°, 21.67±0.20°, and 24.59±0.20°.
[0131] In some embodiments of the present invention, the powder X-ray diffraction pattern of the crystalline form R has characteristic diffraction peaks at 2θ angles of 9.56±0.20°, 14.85±0.20°, 15.49±0.20°, 16.28±0.20°, 18.48±0.20°, 19.13±0.20°, 19.68±0.20°, 21.67±0.20°, 22.80±0.20°, 23.35±0.20°, 24.59±0.20°, and 25.27±0.20°.
[0132] In some embodiments of the present invention, the XRPD spectrum of crystalline form R is shown in FIG.
[0133] In some embodiments of the present invention, the XRPD spectral analysis data for crystalline form R is shown in Table 18: [Table 19]
[0134] In some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form R reaches a weight loss of 2.14% at 160.0±3° C.
[0135] In some embodiments of the present invention, the TGA spectrum of the crystalline form R is shown in FIG.
[0136] The present invention provides use of compounds of formula (II) to formula (VIII), crystalline form A, crystalline form B, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form G, crystalline form H, crystalline form I, crystalline form J, crystalline form K, crystalline form L, crystalline form M, crystalline form N, crystalline form O, crystalline form P, crystalline form Q and crystalline form R in the preparation of a medicament for treating a solid tumor.
[0137] In some aspects of the invention, the solid tumor is a RET kinase related solid tumor. Effect of the Invention
[0138] The compound of the present invention has RET kinase inhibitory activity, excellent PK characteristics and tumor growth inhibitory activity, and the crystalline form of the present invention has stable properties and is promising as a drug.
[0139] (Definitions and Explanations) Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings: A particular term or phrase, unless specifically defined, should not be understood to be "indefinite" or "vague" and should be understood to have its ordinary meaning. When trade names are mentioned herein, it is intended to refer to the corresponding products and their active ingredients.
[0140] The intermediate compounds of the present invention can be prepared by various synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combination with other chemical synthesis means, and equivalent alternative methods known to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.
[0141] The chemical reactions of the specific embodiments of the present invention are carried out in suitable solvents which must be compatible with the chemical reactions of the present invention and the reagents and materials required therefor. In order to obtain the compounds of the present invention, those skilled in the art may need to further modify or select synthetic steps or reaction procedures from the existing embodiments.
[0142] The present invention will be specifically described below using examples, but these examples do not constitute any limitation on the present invention. The abbreviations used in this specification are defined as follows: OTf is represented as trifluoromethanesulfonyl.
[0143] The solvents used in the present invention are all commercially available and can be used without the need for further purification.
[0144] The structure of the compound of the present invention can be confirmed by conventional methods known to those skilled in the art. When the present invention relates to the absolute configuration of a compound, this absolute configuration can be confirmed by conventional technical means in the art. For example, according to single crystal X-ray diffraction (SXRD), the diffraction intensity data is collected from a cultured single crystal using a Bruker D8 venture diffractometer. Light source: CuKα radiation, scanning method: φ / ω scanning. After collecting the relevant data, the crystal structure can be further analyzed by the straight method (Shelxs97) to confirm the absolute configuration.
[0145] Compounds are named according to conventional naming conventions in the art or ChemDraw® software; commercially available compounds use the supplier's catalog name.
[0146] The present invention's X-ray powder diffractometer (XRPD) The powder X-ray diffraction patterns described in the present invention were collected on a Panalytical X'Pert3 powder X-ray diffractometer. The method parameters for the powder X-ray diffraction described in the present invention are as follows: X-ray light source:Cu,Kα Kα1(Å):1.54060; Kα2(Å):1.54443 Kα2 / Kα1 intensity ratio: 0.50 Voltage: 45 kilovolts (kV) Current: 40 milliamps (mA) Divergence slit: fixed 1 / 8 degree Scanning method: Continuous Scanning range: 3.0 to 40.0 degrees (2θ angle) Each step scan time: 46.665 seconds Step width: 0.0263 degrees
[0147] The powder X-ray diffraction patterns described in the present invention were also collected by a DX-2700BH type powder X-ray diffractometer from Dandong Haoyuan Instrument Co., Ltd. The method parameters of the powder X-ray diffraction described in the present invention are as follows: X-rays: Cu, Kα (λ=1.54184Å) Light tube voltage: 40 kilovolts (kV) Phototube current: 30 milliamps (mA) Divergence slit: 1mm First scattering slit: 28 mm Secondary slit: 28mm Detector slit: 0.3 mm Anti-scattering slit: 1mm Scan axis: θs-θd Step width: 0.02 degrees Scan time: 0.5s Scanning range: 3-40 degrees
[0148] Differential scanning calorimeter (DSC) of the present invention The differential scanning calorimetry (DSC) data described in this invention was collected from a TA company Discovery DSC 2500 type differential scanning calorimeter, the control software of the instrument was TRIOS, and the analysis software was Universal Analysis. Typically, 1-5 milligrams of sample was taken and placed in an alumina crucible with a lid, and the sample was heated from room temperature to a set temperature at a heating rate of 10°C / min under the protection of 50mL / min dry N2, and the heat change during the heating process of the sample was recorded by the TA software.
[0149] Thermal Gravimetric Analyzer (TGA) of the present invention The thermogravimetric analysis (TGA) data described in this invention were collected from TA Instruments Q5000 and Discovery TGA 5500 thermogravimetric analyzers, the control software of the instruments was Q Series and TRIOS, respectively, and the analysis software was Universal Analysis. Typically, 1-5 milligrams of sample was taken and placed in a platinum crucible, and the sample was heated from room temperature to 350°C at a heating rate of 10°C / min under the protection of 50 mL / min dry N2.
[0150] Dynamic vapor sorption measurement method of the present invention (Dynamic Vapor Sorption, DVS) Model number: SMS DVS Intrinsic Dynamic Vapor Adsorption Test conditions: Take a sample (10-15 mg) and place it on the DVS sample plate to perform the test.
[0151] The detailed DVS parameters are as follows: Temperature: 25℃ Equilibrium: dm / dt=0.01% / min (minimum: 10min, maximum: 180min) Drying: Dry for 120 minutes under 0% RH. RH(%) Test stage: 10% RH(%) test stage range: 0%-90%-0%
[0152] The moisture absorption rating categories are as follows: [Table 20] [Brief description of the drawings]
[0153] [Figure 1] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form A of compound of formula (I). [Diagram 2] 1 is a DSC spectrum of crystalline form A of compound of formula (I). [Diagram 3] 1 is a TGA spectrum of crystalline form A of compound of formula (I). [Figure 4] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form B of compound of formula (I). [Diagram 5] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form C of compound of formula (I). [Figure 6] 1 is a DSC spectrum of crystalline form C of compound of formula (I). [Figure 7] 1 is a TGA spectrum of crystalline form C of compound of formula (I). [Figure 8] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form D of compound of formula (I). [Figure 9] 1 is an XRPD spectrum of Cu-Kα radiation for crystalline form E of compound of formula (I). [Figure 10] 1 is a DSC spectrum of crystalline form E of compound of formula (I). [Figure 11] 1 is a TGA spectrum of crystalline form E of compound of formula (I). [Figure 12] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form F of compound of formula (I). [Figure 13] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form G of compound of formula (II-1). [Figure 14] 1 is a TGA spectrum of crystalline form G of compound of formula (II-1). [Figure 15] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form H of compound of formula (II-1). [Figure 16] 1 is a TGA spectrum of crystalline form H of compound of formula (II-1). [Figure 17] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form I of the compound of formula (III-1). [Figure 18] 1 is a DSC spectrum of crystalline form I of the compound of formula (III-1). [Figure 19] 1 is a TGA spectrum of crystalline form I of the compound of formula (III-1). [Figure 20] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form J of the compound of formula (IV-1). [Figure 21] 1 is a TGA spectrum of crystalline form J of the compound of formula (IV-1). [Figure 22] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form K of compound of formula (V-1). [Figure 23] 1 is a TGA spectrum of crystalline form K of the compound of formula (V-1). [Figure 24] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form L of the compound of formula (V-1). [Diagram 25] 1 is a TGA spectrum of crystalline form L of the compound of formula (V-1). [Figure 26]1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form M of the compound of formula (VI-1). [Figure 27] 1 is a TGA spectrum of crystalline form M of the compound of formula (VI-1). [Figure 28] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form N of compound of formula (VII-1). [Figure 29] 1 is a TGA spectrum of crystalline form N of compound of formula (VII-1). [Diagram 30] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form O of compound of formula (VII-1). [Diagram 31] 1 is a TGA spectrum of crystalline form O of compound of formula (VII-1). [Diagram 32] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form P of compound of formula (VII-1). [Diagram 33] 1 is a TGA spectrum of crystalline form P of compound of formula (VII-1). [Diagram 34] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form Q of compound of formula (VIII-1). [Diagram 35] 1 is a TGA spectrum of the crystalline form Q of the compound of formula (VIII-1). [Diagram 36] 1 is an XRPD spectrum of Cu-Kα radiation of the crystalline form R of compound of formula (VIII-1). [Figure 37] 1 is a TGA spectrum of the crystalline form R of the compound of formula (VIII-1). [Figure 38] FIG. 2 is a DVS diagram of crystalline form A of compound of formula (I). [Figure 39] 1 is an XRPD spectrum of Cu-Kα radiation of crystalline form A of compound of formula (I). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0154] In order to better understand the present invention, the present invention will be further described below in conjunction with specific examples, but the specific embodiments are not intended to limit the present invention.
[0155] Example 1: Preparation of the compound of formula (I) and its trifluoroacetate salt [ka]
[0156] [ka]
[0157] [ka]
[0158] Step 1 2,5-Dibromopyrazine (4g, 16.82mmol) and 6-tert-butoxycarbonyl-3,6-diazabicyclo[3.1.1]-heptane (4.00g, 20.18mmol) were dissolved in N-methylpyrrolidone (50mL), diisopropylethylamine (6.52g, 50.45mmol, 8.79mL) was added, and the mixture was stirred at 100°C for 16 hours. 60mL of water was added, and the mixture was extracted with ethyl acetate (100mL x 3), and the organic phases were combined, washed with water (150mL x 5), washed with saturated sodium chloride solution (150mL x 1), dried with anhydrous sodium sulfate, and finally, the solvent was spin-dried to obtain the crude product. The crude product was purified by an automatic column machine (petroleum ester: ethyl acetate = 4:1) to obtain compound 1. LCMS(ESI)m / z:354.9[M+1] + ,356.9[M+3] + ; 1 HNMR(400MHz,CDCl3)δ8.15(d,J=1.2Hz,1H),7.77(s,1H),4.28-4.31(m,2H),3.90-4.12 (m,2H),3.42(d,J=12.0Hz,2H),2.64-2.72(m,1H),1.50(d,J=12.4Hz,1H),1.38(s,9H).
[0159] Step 2 Compound 1 (3 g, 8.45 mmol) was dissolved in ethyl acetate (15 mL), hydrogen chloride / ethyl acetate (4 M, 20 mL) was added, and the mixture was stirred for 3 hours at 16° C. The solvent was spin-dried to obtain crude product 2, which was used in the next reaction without purification. LCMS(ESI)m / z:254.9[M+1] + ,256.9[M+3] + .
[0160] Step 3 Compound 2 (2.45 g, 8.40 mmol) and 6-methoxy-3-pyridinecarbaldehyde (2.30 g, 16.81 mmol) were added to DCM (50 mL), and sodium borohydride acetate (5.34 g, 25.21 mmol) was added and stirred at 16 ° C for 1.5 hours. The reaction solution became clear, and 50 mL of water was added to the reaction solution, and it was extracted with dichloromethane (50 mL × 3), and the organic phase was combined, washed with saturated sodium chloride solution (100 mL × 1), dried with anhydrous sodium sulfate, and finally, the solvent was spin-dried to obtain the crude product. The crude product was purified by an automatic column machine (petroleum ester: ethyl acetate = 1: 3 to dichloromethane: methanol = 10: 1) to obtain compound 3. LCMS(ESI)m / z:376.0[M+1] + ,378.0[M+3] + .
[0161] Step 4 Compound 3 (1.8 g, 4.78 mmol) and bis(pinacolato)diboron (1.82 g, 7.18 mmol) were dissolved in 1,4-dioxane (15 mL), and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (350.05 mg, 478.40 μmol) and potassium acetate (1.41 g, 14.35 mmol) were added and stirred at 80 °C for 16 h under nitrogen atmosphere. Partial halogen-free by-products were formed in the reaction, and the reaction solution was directly filtered and washed twice with ethyl acetate. The filtrate was spin-dried to obtain crude product 4, which was used directly in the next reaction. LCMS(ESI)m / z:342.1[M+1] + .
[0162] Step Five 3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester (1.5 g, 7.14 mmol), compound 5 (1.80 g, 7.14 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (261.23 mg, 357.01 μmol) and potassium phosphate (4.55 g, 21.42 mmol) were added in one portion to 1,4-dioxane (12 mL) and water (6 mL), and the mixture was heated to 100 °C under nitrogen atmosphere using a microsynth and reacted with stirring for 30 minutes. The reaction mixture was extracted with 20 mL water and 20 mL ethyl acetate, separated, and the aqueous phase was further extracted with 20 mL ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain the crude product. The crude product was purified by flash silica gel column (petroleum ester / ethyl acetate = 1 / 1) to obtain compound 6. LCMS(ESI)m / z:255.9[M+1] + .
[0163] Step 6 Pyridine hydrochloride (4.53 g, 39.17 mmol) was added to compound 6 (1 g, 3.92 mmol), and the mixture was heated to 180°C in a microwave oven under nitrogen atmosphere and stirred for 20 minutes. Saturated aqueous sodium bicarbonate was added to the reaction solution until the pH value reached 7. 50 mL of ethyl acetate was added to extract and separate the mixture. The aqueous phase was extracted with 50 mL of ethyl acetate, and the organic phases were combined and dried over anhydrous sodium sulfate. The solvent was removed by rotary evaporation to obtain crude product 7, which was used in the next reaction without further purification.
[0164] Step Seven Compound 7 (460 mg, 1.91 mmol), N-phenylbis(trifluoromethylsulfonyl)imide (1.02 g, 2.86 mmol) and diisopropylethylamine (739.31 mg, 5.72 mmol) were added in one portion to N,N-dimethylformamide (10 mL), and the mixture was stirred for 16 hours under nitrogen atmosphere at 10-20° C. The reaction mixture was added directly to 50 mL water, and extracted with 20 mL ethyl acetate, separated, and the aqueous phase was further extracted with 20 mL ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation to obtain crude product 8.
[0165] Step Eight Compound 8 (560 mg, 1.50 mmol), compound 4 (511.79 mg, 1.50 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (54.88 mg, 75.01 μmol) and potassium phosphate (955.27 mg, 4.50 mmol) were added in one portion to 1,4-dioxane (12 mL) and water (6 mL), and the mixture was heated to 90°C under nitrogen atmosphere using a microsynth and reacted with stirring for 0.5 hours. 20 mL water and 20 mL ethyl acetate were added to the reaction solution, the liquids were separated, and the aqueous phase was extracted with 20 mL ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and rotary evaporated to obtain the crude product of formula (I). The crude product was sent to a preparation column (YMC-Triart Prep C18 150×40mm×7μm; mobile phase: [water (0.1% TFA)-ACN]; acetonitrile: 30%-40%, 10min) for separation and purification to obtain the trifluoroacetate salt of compound (I). The trifluoroacetate salt of compound (I) was added to sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound (I). LCMS(ESI)m / z:521.1[M+1] + ; 1HNMR(400MHz,CD3OD)δ8.81~8.80(m,1H),8.71~8.65(m,1H),8.48~8.45(m,1H),8.40 ~8.30(m,2H),8.00~7.92(m,1H),7.90~7.92(m,1H),6.95~6.92(m,2H),6.53(s,1H),4 .74~4.71(m,2H),4.63~4.61(d,J=8Hz,1H),4.39~4.37(m,2H),4.43~4.30(m,3H),4.1 0~4.06(m,1H),4.00~3.96(m,6H),3.65~3.62(m,1H),2.62(s,2H),2.25~2.21(m,1H).
[0166] Example 2: Preparation of crystalline form A of compound of formula (I) The crude product of formula (I) was applied to a silica gel column, and then purified using an automatic column machine (dichloromethane:methanol=20:1) to obtain the compound of formula (I). 200 ml of methanol (40 times) was added to 5 g of the compound of formula (I) and the mixture was beaten for 16 hours overnight, and a solid precipitated. The solid was filtered to obtain the crystalline form A of the compound of formula (I). Its XRPD spectrum is shown in Figure 1, its DSC spectrum is shown in Figure 2, and its TGA spectrum is shown in Figure 3.
[0167] About 6L of methanol was added to about 400g of the crude product of formula (I), and the mixture was stirred at 20-30°C for 88-96 hours. The reaction solution was filtered, and the filter cake was washed with methanol (0.5L) and dried in vacuum for 16-24 hours. 5.78L of purified water was added to the obtained solid, and the temperature was controlled at 90-100°C, and the mixture was stirred for 24-48 hours. The temperature was lowered to 20-30°C, and the reaction solution was filtered and dried in vacuum for 40-96 hours to obtain crystalline form A. Its XRPD spectrum is shown in Figure 39.
[0168] Example 3: Preparation of crystalline form B of compound of formula (I) The compound of formula (I) (20.9 mg) was added to 1.0 mL of 1,4-dioxane, and the mixture was stirred at room temperature to obtain a suspension, which was then centrifuged and dried to obtain a solid, which was identified as the crystalline form B of the compound of formula (I). The XRPD spectrum of the solid is shown in FIG.
[0169] Example 4: Preparation of crystalline form C of compound of formula (I) Crystal form B of compound of formula (I) was left open overnight at room temperature, and the resulting solid was identified as crystal form C of compound of formula (I). Its XRPD spectrum is shown in FIG. 5, DSC spectrum is shown in FIG. 6, and TGA spectrum is shown in FIG.
[0170] Example 5: Preparation of crystalline form D of compound of formula (I) The crystal form A of the compound of formula (I) (20.6 mg) was added to 0.5 mL of 1,4-dioxane / n-butyl alcohol (volume ratio 1:1) and stirred at room temperature for 5 days to form a suspension, which was centrifuged and dried to obtain a solid, which was identified as the crystal form D of the compound of formula (I). Its XRPD spectrum is shown in FIG.
[0171] Example 6: Preparation of crystalline form E of compound of formula (I) The compound of formula (I) (20.6 mg) was added to 2.0 ml of acetone and stirred at 50° C. for 1 hour to obtain a suspension, which was then filtered to obtain a supernatant, which was cooled from 50° C. to 5° C. within 40 hours to precipitate a small amount of solid, which was then allowed to stand at −20° C. After 6 days, the solid was obtained, centrifuged, and dried to obtain crystalline form E of the compound of formula (I). Its XRPD spectrum is shown in FIG. 9, its DSC spectrum is shown in FIG. 10, and its TGA spectrum is shown in FIG. 11.
[0172] Example 7: Preparation of crystalline form F of compound of formula (I) The compound of formula (I) (20.5 mg) was added to 2.0 ml of dimethyltetrahydrofuran and stirred at 50° C. for 1 hour to obtain a suspension, which was then filtered to obtain a supernatant, which was cooled from 50° C. to 5° C. within 40 hours to precipitate a small amount of solid, which was then allowed to stand at −20° C. After 6 days, the solid was obtained, centrifuged, and dried to obtain crystalline form F of the compound of formula (I). Its XRPD spectrum is shown in FIG.
[0173] Example 8: Preparation of crystalline form G of compound of formula (II-1) [ka]
[0174] The compound of formula (I) (19.9 mg) was added to 0.5 mL of ethanol / water (volume ratio 9:1) containing 4.8 mg of maleic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (II-1) crystalline form G. Its XRPD spectrum is shown in FIG. 13, and its TGA spectrum is shown in FIG. 14.
[0175] Example 9: Preparation of crystalline form H of compound of formula (II-1) The compound of formula (I) (20.7 mg) was added to 0.5 ml of acetone containing 4.8 mg of maleic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (II-1) crystalline form H. Its XRPD spectrum is shown in FIG. 15, and its TGA spectrum is shown in FIG. 16.
[0176] Example 10: Preparation of crystalline form I of compound of formula (III-1) [ka]
[0177] The compound of formula (I) (20.5 mg) was added to 0.5 ml of ethanol / water (volume ratio 9:1) containing 8.6 mg of mucic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (III-1) crystalline form I. Its XRPD spectrum is shown in Figure 17, its DSC spectrum is shown in Figure 18, and its TGA spectrum is shown in Figure 19.
[0178] Example 11: Preparation of crystalline form J of compound of formula (IV-1) [ka]
[0179] The compound of formula (I) (19.1 mg) was added to 0.5 mL of ethanol / water (volume ratio 9:1) containing 5.8 mg of tartaric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (IV-1) crystalline form J. Its XRPD spectrum is shown in FIG. 20, and its TGA spectrum is shown in FIG. 21.
[0180] Example 12: Preparation of crystalline form K of compound of formula (V-1) [ka]
[0181] The compound of formula (I) (20.4 mg) was added to 0.5 mL of ethanol / water (volume ratio 9:1) containing 4.4 mg of fumaric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (V-1) crystal form K. Its XRPD spectrum is shown in FIG. 22, and its TGA spectrum is shown in FIG. 23.
[0182] Example 13: Preparation of crystalline form L of compound of formula (V-1) The compound of formula (I) (20.7 mg) was added to 0.5 ml of acetone containing 4.6 mg of fumaric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (V-1) crystalline form L. Its XRPD spectrum is shown in FIG. 24, and its TGA spectrum is shown in FIG. 25.
[0183] Example 14: Preparation of crystalline form M of compound of formula (VI-1) [ka]
[0184] The compound of formula (I) (19.4 mg) was added to 0.5 mL of acetone containing 7.4 mg of citric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VI-1) crystalline form M. Its XRPD spectrum is shown in FIG. 26, and its TGA spectrum is shown in FIG. 27.
[0185] Example 15: Preparation of crystalline form N of compound of formula (VII-1) [ka]
[0186] The compound of formula (I) (19.9 mg) was added to 0.5 mL of ethanol / water (volume ratio 9:1) containing 5.0 mg of oxalic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VII-1) crystalline form N. Its XRPD spectrum is shown in FIG. 28, and its TGA spectrum is shown in FIG. 29.
[0187] Example 16: Preparation of crystalline form O of compound of formula (VII-1) The compound of formula (I) (19.8 mg) was added to 0.5 ml of acetone containing 5.5 mg of oxalic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VII-1) crystalline form O. Its XRPD spectrum is shown in FIG. 30, and its TGA spectrum is shown in FIG. 31.
[0188] Example 17: Preparation of crystalline form P of compound of formula (VII-1) The compound of formula (I) (19.3 mg) was added to 0.5 mL of ethyl acetate containing 5.1 mg of oxalic acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VII-1) crystalline form P. Its XRPD spectrum is shown in FIG. 32, and its TGA spectrum is shown in FIG. 33.
[0189] Example 18: Preparation of crystalline form Q of compound of formula (VIII-1) [ka]
[0190] The compound of formula (I) (19.3 mg) was added to 0.5 mL of ethanol / water (volume ratio 9:1) containing 3.9 mg of phosphoric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VIII-1) crystalline form Q. Its XRPD spectrum is shown in FIG. 34, and its TGA spectrum is shown in FIG. 35.
[0191] Example 19: Preparation of crystalline form R of compound of formula (VIII-1) The compound of formula (I) (19.7 mg) was added to 0.5 mL of acetone containing 4.4 mg of phosphoric acid, and after stirring at room temperature for 2 days, a suspension was formed. After centrifugation, the solid was vacuumed at room temperature for 1 hour, and the resulting solid was identified as the compound of formula (VIII-1) crystalline form R. Its XRPD spectrum is shown in FIG. 36, and its TGA spectrum is shown in FIG. 37.
[0192] Example 20: Hygroscopicity study of crystalline form A of compound of formula (I) Test materials: SMS DVS Intrinsic Dynamic Vapor Adsorption
[0193] Testing Method: The test is carried out by placing 10 to 15 mg of the crystalline form A of the compound of formula (I) in the DVS sample plate.
[0194] Test Results: The DVS spectrum of crystalline form A of compound of formula (I) is shown in FIG. 38, with ΔW=0.8%.
[0195] Test conclusion: The hygroscopic weight gain of the crystalline form A of the compound of formula (I) at 25° C. and 80% RH is 0.8%, and the compound is somewhat hygroscopic.
[0196] Example 21: Solid-state stability experiment of crystalline form A of compound of formula (I) According to the "Guiding Principles for Stability Testing of Raw Materials and Preparations" (Chinese Pharmacopoeia 2015 Edition, Four General Principles 9001), the stability of crystalline form A of compound of formula (I) under high temperature (60°C, open) and high humidity (room temperature / relative humidity 92.5%, open) conditions was considered.
[0197] 15 mg of the crystalline form A of the compound of formula (I) was weighed and placed on the bottom of a glass sample bottle and spread thinly. The bottle mouth of the sample left under high temperature and high humidity conditions was sealed with aluminum foil paper, and a small hole was made on the aluminum foil paper to ensure sufficient contact between the sample and the ambient air. The samples left under different conditions were sampled and detected (XRPD) on the 5th and 10th days, and the detection results were compared with the initial detection results on day 0. The test results are shown in Table 19: [Table 21]
[0198] Conclusion: The crystalline form A of the compound of formula (I) has good stability under high temperature and high humidity conditions.
[0199] Example 22: Solid-state stability study of crystalline form A of compound of formula (I) According to the "Guiding Principles for Stability Testing of Raw Materials and Preparations" (Chinese Pharmacopoeia 2015, Four Parts General Principles 9001), the stability of the crystalline form A of the compound of formula (I) under long-term experimental conditions was examined. Approximately 10 mg of the crystalline form A of the compound of formula (I) was weighed, placed on the bottom of a glass sample bottle, spread thinly, the bottle mouth was sealed with aluminum foil paper, a small hole was made on the aluminum foil paper, and the sample was left at (40°C / 75%RH) for 3 months and at (25°C / 60%RH) for 3 months. XRPD characteristics were evaluated for the sample after the leaving, and the detection results were compared with the initial detection results on day 0. The results are shown in Table 20, and the crystalline form A of the compound of formula (I) did not change in either crystal form under all stability conditions.
[0200] The test results are shown in Table 20 below: [Table 22]
[0201] Experimental Conclusion: The crystalline form A of the compound of formula (I) has good stability.
[0202] Biomedical Experiment Data Experimental Example 1: In vitro enzyme activity test of the compound of the present invention Purpose of the experiment Z'-LYTE™ Kinase Test Experiments were used to detect enzyme activity and determine the IC 50 The inhibitory effect of the compounds on RET and RET(V804M) kinase was evaluated using the values as indices.
[0203] Experimental Method The compounds used to test RET and RET(V804M) kinases were diluted in 3-fold concentrations, with 10 concentrations ranging from 3 μM to 0.152 nM, and the DMSO content in the detection reaction was 1%.
[0204] reagent: Elementary reaction buffer, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (pH 7.5) buffer, 10 mM MgCl2, 1 mM ethylenebis[(oxyethylene)nitrilo]tetraacetic acid (EGTA), 0.02% polyoxyethylene dodecyl ether (Brij35), 0.02 mg / mL bovine serum albumin, 0.1 mM Na3VO4, 2 mM dithiothreitol (DTT), 1% DMSO.
[0205] Compound: The test compounds were dissolved in 100% DMSO and diluted to 10 mM before use. The solution was diluted using an Integra Viaflo Assist.
[0206] Reaction process of general enzymes: Test conditions: RET enzyme concentration was 3 μM, peptide substrate CHKtide concentration was 1000 μM, ATP concentration was 20 μM, RET(V804M) enzyme concentration was 80 μM, substrate peptide concentration was 1000 μM, and ATP concentration was 30 μM.
[0207] Reaction process: Kinase / polypeptide solutions were prepared according to the test conditions. Compound solutions of different concentrations were added and incubated at room temperature for 20 minutes, and 33P-ATP of the corresponding concentration was added and incubated at room temperature for 120 minutes. Radioactivity was detected by the filter-binding method.
[0208] Reaction detection: The kinase reactions were stopped by adding 0.5% phosphoric acid and read on the Envision instrument.
[0209] Data analysis Data were converted to phosphorylation rates and inhibition rates, and parameters were curve-fitted (GraphPad Software) to obtain compound IC values. 50 We got the data.
[0210] The experimental results are shown in Table 21: [Table 23]
[0211] Experimental conclusion: The compound of the present invention has excellent inhibitory activity against RET and its mutant RET V804M, and is expected to have excellent therapeutic effect in patients with RET abnormal tumors.
[0212] Experimental Example 2: Pharmacokinetic evaluation of the compounds of the present invention Experimental procedure: 0.1 mg / mL of the test compound in the corresponding vehicle (see Table 22) was administered to female Balb / c mice (fasted overnight, 7-9 weeks old) via tail vein injection at a dose of 0.2 mg / kg. After intravenous administration, approximately 30 μL of blood was collected from the jugular or tail vein at 0.0833, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 24 h. 0.2 mg / mL of the test compound suspended in the corresponding vehicle (see Table 22) was administered to female Balb / c mice (fasted overnight, 7-9 weeks old) via intragastric administration at a dose of 2 mg / kg. The details of the experimental conditions are shown in Table 22. After oral administration, approximately 30 μL of blood was collected from the jugular or tail vein of female Balb / c mice at 0.0833, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 and 24 h. The blood was placed in an anticoagulant tube containing EDTA-K2, and the plasma was centrifuged. The blood concentration was measured by LC-MS / MS, and the relevant pharmacokinetic parameters were calculated using the non-compartmental linear logarithmic trapezoidal method with WinNonlin™ Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software. The experimental results are shown in Table 23.
[0213] [Table 24]
[0214] [Table 25]
[0215] Conclusion: The experimental results showed that when administered intravenously, all of the compounds of the present invention showed low elimination rates, low distribution volumes, relatively long half-lives, and excellent drug exposure.When administered orally, all of the compounds of the present invention showed relatively rapid peak arrival, excellent oral absorption exposure, and overall excellent oral absorption bioavailability.
[0216] Experimental Example 3: Tumor Growth Inhibition (TGI) Assay The Ba / F3-CCDC6-RET cell line was cultured at 37°C, 5% CO2 in 1640 medium (Biological Industries) + 10% fetal bovine serum (BI) + 1% diabody (Penicillin Streptomycin solution, Coring, USA) and subcultured twice a week. When the cell saturation reached 80%-90%, the cells were harvested, counted, and inoculated subcutaneously into the right armpit of BALB / c nude female mice (6-8 weeks old). After completion of inoculation, the tumor growth status was observed daily, and the average tumor volume was approximately 165.77 mm. 3 Once tumor volume reached 100 mg / kg, mice were randomly assigned to groups of 6 mice per group based on tumor volume and treatment was initiated.
[0217] The animals were checked daily for health and mortality. Routine checks included tumor growth, activity, feeding, weight, eyes, hair and other abnormal behaviors. Tumor volume and weight were measured twice a week (Tuesdays and Fridays).
[0218] The inhibitory effect of the compound on tumor growth was evaluated by the relationship between tumor volume and time. The tumor volume was measured with a caliper and the formula was TV=0.5a×b 2 where a is the long diameter of the tumor and b is the short diameter of the tumor. The TGI is calculated from the difference between the median tumor volume of the vehicle group mice and the median tumor volume of the drug group mice, and is expressed as a percentage of the median tumor volume of the vehicle control group, and is calculated according to the following formula: TGI(TGI(%)=[1-(T 23- T0) / (V 23 -V0)] x 100)
[0219] Unless otherwise stated, data are expressed as mean ± standard error (Mean ± SE) and tumor volumes of treated groups were compared with those of control groups by one-way ANOVA test to determine whether there was a significant difference. P<0.05 indicates a significant difference. 5% DMSO + 10% polyethylene glycol-15 hydroxystearate (Solutol) + 85% H2O was the negative control. The experimental results are shown in Table 24.
[0220] [Table 26]
[0221] Conclusion: The compound of the present invention showed excellent tumor growth inhibitory effects in the tumor model Ba / F3-CCDC6-RET.
Claims
1. Crystal A of the compound of formula (I) is characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at 2θ angles of 16.30±0.20°, 21.69±0.20°, and 24.63±0.20°. 【Chemical 1】
2. The powder X-ray diffraction pattern of crystalline A of claim 1 has characteristic diffraction peaks at 2θ angles of 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69±0.20°, and 24.63±0.20°.
3. The powder X-ray diffraction pattern of crystalline A according to claim 2 has characteristic diffraction peaks at 2θ angles of 7.79±0.20°, 9.58±0.20°, 12.61±0.20°, 14.88±0.20°, 15.51±0.20°, 16.30±0.20°, 18.49±0.20°, 19.16±0.20°, 19.70±0.20°, 21.69±0.20°, and 24.63±0.20°.
4. The crystalline A according to any one of claims 1 to 3, wherein the XRPD spectrum has characteristic diffraction peaks at the following 2θ angles: 【Table 1】
5. The crystalline A according to any one of claims 1 to 3, wherein the differential scanning calorimetry curve has an onset value of one endothermic peak at 188.7±2°C.
6. The crystalline A according to any one of claims 1 to 3, wherein the thermogravimetric analysis curve reaches a weight loss of 1.20% at 180.0±3°C.
7. Use of Crystalline A of compound of formula (I) according to any one of claims 1 to 6 in the preparation of a medicament for treating solid tumors.
8. The use according to claim 7, wherein the solid tumor is a solid tumor associated with RET kinase.
Citation Information
Patent Citations
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JP2018532690A
1,2-Dithiolane Compounds Useful in Neuroprotective, Autoimmune, and Cancer Diseases and Conditions
JP2019534857A
Compounds useful as RET inhibitors
JP2020516636A
Pyrazolopyridine compound as RET inhibitor and application thereof
WO2020200316A1
